August 14, 2014 | RedHill BioPharma, an emerging Israeli biopharmaceutical company focusing on the treatment of inflammatory and gastrointestinal diseases, has acquired an option for a Phase II pancreatic cancer drug RP101. RedHill acquired the cancer-treating drug from Dresden, Germany-based company RESprotect GmbH, a spin-off of the Fraunhofer Society. According to RedHIll, RP101 has completed Phase I and II clinical trials and has been granted the Orphan Drug designation for the treatment of pancreatic cancer by the United States Food & Drug Administration (FDA) and the European Medicines Agency (EMA).
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts
New Program Supporting Early-Stage Construction Startups In North
October 13, 2024
IAI Launches First US Innovation Center, New Accelerator Program
October 13, 2024
Israeli Cybersecurity Startup To Provide Training For IDF
October 10, 2024
Johnson & Johnson Completes Purchase Of Israeli Startup V-Wave
October 10, 2024
Facebook comments